Pulmatrix Announces Grant of Patent Supporting Its Novel Pulmonary Drug Therapies
Published: Jan 05, 2012
LEXINGTON, Mass.--(BUSINESS WIRE)--Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, announced that the European Patent Office has granted Pulmatrix’s patent number EP 2315580 B1 entitled “Pharmaceutical formulations and methods for treating respiratory tract infections”, a patent relating to compositions and uses of the company’s inhaled drug therapies. The newly-granted patent describes both dry powder and liquid formulations with optimized ranges of the formulation components, and also describes methods for treating respiratory infections and diseases as well as methods for treating acute exacerbations of asthma, chronic obstructive pulmonary disease (COPD) or cystic fibrosis (CF). The granted patent also specifically contains composition of matter claims covering Pulmatrix’s lead dry powder iCALM formulation, PUR118, which is being evaluated in ongoing clinical trials, including two on-going Phase 1b studies in patients with COPD which includes patients with emphysema and chronic bronchitis.